Sonoma Pharma | 10-Q: FY2026 Q2 Revenue: USD 5.604 M

Revenue: As of FY2026 Q2, the actual value is USD 5.604 M.

EPS: As of FY2026 Q2, the actual value is USD -0.32, missing the estimate of USD -0.31.

Segment Revenue

• United States: Revenue increased by $774,000, or 115%, to $1,449,000 for the three months ended September 30, 2025, primarily due to increased sales of human health care and over-the-counter animal health care products.
• Europe: Revenue increased by $645,000, or 43%, to $2,151,000, driven by a general increase in demand for products.
• Asia: Revenue increased by $281,000, or 36%, to $1,057,000, primarily due to timing of orders.
• Latin America: Revenue increased by $67,000, or 14%, to $532,000, primarily due to timing of customer orders.
• Rest of the World: Revenue increased by $258,000, or 164%, to $415,000, primarily due to timing of customer orders.

Operational Metrics

• Net Loss: The net loss for the three months ended September 30, 2025, was $534,000, compared to $610,000 for the same period in 2024.
• Gross Profit: Increased by $759,000, or 56%, to $2,120,000 for the three months ended September 30, 2025, due to increased revenue and product mix.
• Operating Expenses: Total operating expenses increased by $246,000, or 11%, to $2,457,000 for the three months ended September 30, 2025.

Cash Flow

• Net Cash Used in Operating Activities: For the six months ended September 30, 2025, net cash used in operating activities was - $2,650,000, compared to - $558,000 for the same period in 2024.
• Net Cash Used in Investing Activities: For the six months ended September 30, 2025, net cash used in investing activities was - $116,000, primarily related to the purchase of equipment.
• Net Cash Used in Financing Activities: For the six months ended September 30, 2025, net cash used in financing activities was - $120,000, primarily related to the exercise of stock options and principal payments on a short-term loan.

Future Outlook and Strategy

• Core Business Focus: Sonoma Pharmaceuticals, Inc. plans to continue expanding its product offerings and market reach, particularly in dermatology and wound care, leveraging its HOCl technology. The company aims to increase revenue through strategic partnerships and direct sales efforts in the U.S. and international markets.
• Non-Core Business: The company is exploring opportunities in animal health care and surface disinfectants, with a focus on expanding distribution through partnerships in Europe, the Middle East, and Australia.